Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ozanimod is an oral sphingosine-1-phosphate receptor agonist targeting subtypes 1 and 5.
• It induces peripheral lymphocyte sequestration, potentially reducing gastrointestinal tract inflammation.

Purpose of the Study:

• To evaluate the efficacy and safety of ozanimod in adults with moderate-to-severe ulcerative colitis.
• To determine optimal dosing for clinical remission and response.

Main Methods:

• A double-blind, placebo-controlled phase 2 trial involving 197 adults with ulcerative colitis.
• Patients received daily doses of 0.5 mg ozanimod, 1 mg ozanimod, or placebo for up to 32 weeks.
• Disease activity was assessed using the Mayo Clinic score; primary outcome was clinical remission at 8 weeks.

Main Results:

• The 1 mg ozanimod group achieved a significantly higher clinical remission rate (16%) compared to placebo (6%) at 8 weeks (P=0.048).
• Clinical response rates at 8 weeks were 57% for 1 mg ozanimod and 54% for 0.5 mg ozanimod, versus 37% for placebo.
• At 32 weeks, clinical remission rates were 21% (1 mg ozanimod), 26% (0.5 mg ozanimod), and 6% (placebo).
• Common adverse events included anemia and headache.

Conclusions:

• A daily 1 mg dose of ozanimod demonstrated a higher rate of clinical remission in ulcerative colitis compared to placebo in this preliminary study.
• The trial's size and duration were insufficient to definitively establish clinical efficacy or safety.
• Further investigation is warranted to confirm ozanimod's therapeutic potential in ulcerative colitis.